Sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affects central regulation of appetite and satiety, which results in increased carbohydrate intake. It has now been demonstrated that these effects might be blunted by combining SGLT2 inhibitors with glucagon-like peptide 1 receptor agonists to further facilitate weight loss in patients with type 2 diabetes mellitus.

中文翻译：

---

GLP1 受体激动剂克服 SGLT2 抑制剂相关的暴饮暴食

钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂治疗会影响食欲和饱腹感的中枢调节，从而导致碳水化合物摄入量增加。现在已经证明，将 SGLT2 抑制剂与胰高血糖素样肽 1 受体激动剂联合使用可能会减弱这些作用，从而进一步促进 2 型糖尿病患者的体重减轻。